Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Candriam S.C.A.

Candriam S.C.A. lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 17.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 944,332 shares of the medical equipment provider’s stock after selling 193,047 shares during the period. Candriam S.C.A. owned about 0.42% of Hologic worth $68,077,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC grew its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after buying an additional 544,889 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Hologic during the fourth quarter worth about $27,007,000. Swedbank AB grew its holdings in shares of Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after buying an additional 238,222 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $62.08 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 12 month low of $61.70 and a 12 month high of $84.67. The firm has a market capitalization of $13.93 billion, a price-to-earnings ratio of 19.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The business’s 50 day simple moving average is $68.77 and its 200-day simple moving average is $75.64.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HOLX. Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Raymond James reaffirmed an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Royal Bank of Canada lowered their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic has an average rating of “Hold” and an average target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.